Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

To grow and metastasize, solid tumours must develop their own blood supply by neo-angiogenesis. Thalidomide inhibits the processing of mRNA encoding peptide molecules including tumour necrosis factor-alpha (TNF-α) and the angiogenic factor vascular endothelial growth factor (VEGF). This study invest...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Eisen, T, Boshoff, C, Mak, I, Sapunar, F, Vaughan, M M, Pyle, L, Johnston, S R D, Ahern, R, Smith, I E, Gore, M E
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2000
Témata:
Regular Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2374399/
https://ncbi.nlm.nih.gov/pubmed/10732751
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1054/bjoc.1999.1004
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky